Samsung Pharm (001360) — Cash Flow-to-Debt Ratio
Samsung Pharm (001360) has a Cash Flow-to-Debt Ratio of -0.05x as of September 2025, meaning its operating cash flow of ₩-2.29 Billion could theoretically repay 0% of its total liabilities (₩44.04 Billion) in one year. Explore Samsung Pharm long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Samsung Pharm Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Samsung Pharm across 12 annual periods. Also explore Samsung Pharm (001360) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Samsung Pharm (2012–2024)
Year-by-year debt coverage analysis for Samsung Pharm. For market capitalisation and broader financial context, see Samsung Pharm stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.77x | ₩-17.30 Billion | ₩22.60 Billion | ▲ +56.0% |
| 2023 | -1.74x | ₩-27.66 Billion | ₩15.89 Billion | ▼ -1293.0% |
| 2022 | -0.12x | ₩-1.91 Billion | ₩15.32 Billion | ▲ +68.3% |
| 2021 | -0.39x | ₩-7.16 Billion | ₩18.19 Billion | ▼ -776.4% |
| 2020 | -0.04x | ₩-2.55 Billion | ₩56.81 Billion | ▲ +52.5% |
| 2019 | -0.09x | ₩-2.43 Billion | ₩25.70 Billion | ▲ +57.9% |
| 2018 | -0.22x | ₩-6.52 Billion | ₩28.98 Billion | ▼ -363.4% |
| 2017 | 0.09x | ₩5.15 Billion | ₩60.33 Billion | ▲ +148.0% |
| 2016 | -0.18x | ₩-9.94 Billion | ₩55.91 Billion | ▼ -255.1% |
| 2015 | -0.05x | ₩-4.20 Billion | ₩83.98 Billion | ▲ +87.4% |
| 2014 | -0.40x | ₩-13.58 Billion | ₩34.12 Billion | ▼ -144.4% |
| 2012 | -0.16x | ₩-11.13 Billion | ₩68.31 Billion | — |